NDAINTRAVENOUSINJECTABLE2 Generics Approved
Approved
Jul 2006
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEPPRA (levetiracetam) is a small-molecule antiepileptic drug approved as an intravenous injectable formulation for seizure management. It is used across multiple seizure types and indications, with a mechanism of action distinct from traditional anticonvulsants. The IV route enables acute seizure control and hospital-based therapeutic interventions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (60/100), signaling defensive portfolio positioning and likely cost-containment focus within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
Started May 2021
110 enrolled
Focal Onset Seizures
An Investigation of Levetiracetam in Alzheimer's Disease
Started Oct 2018
8 enrolled
Alzheimer DiseaseEpilepsy
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
Started Nov 2017
38 enrolled
Partial Seizures
Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
Started Jan 2016
15 enrolled
Subarachnoid Hemorrhage
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
Started Nov 2015
13 enrolled
Healthy Volunteers
Worked on KEPPRA at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.